TRIM5α and TRIMCyp are retroviral restriction factors that, like other members of the tripartite motif (TRIM) family, contain RING, B-box 2 and coiled-coil domains. We found that both proteins are rapidly turned over, with half-lives of 50-60 min. Polyubiquitylation and rapid degradation of TRIM5α depended upon intact RING and B-box 2 domains. A chimera consisting of monkey TRIM5α with a RING domain of human TRIM21 exhibited a half-life of 210 min, yet potently restricted human immunodeficiency virus; therefore, rapid turnover of TRIM5α is not required for its antiretroviral activity. TRIM5α forms cytoplasmic bodies that contain other polyubiquitylated proteins, heat shock proteins and dynein, and thus resemble aggresome precursors. Consistent with this interpretation, proteasomal inhibitors triggered the formation of TRIM5α rhcontaining aggresomes in a microtubule-dependent manner. Thus, TRIM5α levels in the cell are maintained by continuous synthesis and rapid proteasome-mediated degradation, imbalances in which result in the formation of pre-aggresomal cytoplasmic bodies.
Introduction
Proteins of the tripartite motif (TRIM) family contain RING, B-box and coiled-coil domains and thus have also been referred to as RBCC proteins. TRIM proteins often self-associate and form nuclear or cytoplasmic bodies (Reymond et al., 2001 ). The number of TRIM genes has greatly increased during vertebrate evolution, although the natural function of most TRIM proteins is unknown.
TRIM5α is a cytoplasmic protein that is capable of restricting retrovirus infection in a species-dependent manner . Variation among TRIM5α proteins in different primates accounts for the early, post-entry blocks to infection by particular retroviruses (Hatziioannou et al., 2004; Keckesova et al., 2004; Perron et al., 2004; Song et al., 2005a; Stremlau et al., 2004; Yap et al., 2004) . For example, TRIM5α proteins of Old World monkeys block human immunodeficiency virus (HIV-1) infection (Hatziioannou et al., 2004; Keckesova et al., 2004; Stremlau et al., 2004; Yap et al., 2004) , whereas TRIM5α proteins of New World monkeys block infection by simian immunodeficiency virus (SIV mac ) (Song et al., 2005a) . TRIM5α from humans (TRIM5α hu ) is not as potent in restricting HIV-1 infection as Old World monkey TRIM5α, but TRIM5α hu potently restricts other retroviruses, e.g., N-tropic murine leukemia virus (N-MLV) and equine infectious anemia virus (EIAV) (Hatziioannou et al., 2004; Perron et al., 2004; Song et al., 2005a; Stremlau et al., 2004; Yap et al., 2004) . Owl monkeys are unusual in not expressing a TRIM5α protein, but instead express TRIMCyp, in which the RBCC domains of TRIM5 are fused to a cyclophilin A moiety Sayah et al., 2004) .
Variation in splicing of the TRIM5 primary transcript leads to the expression of TRIM5 isoforms, designated α, γ and δ (Reymond et al., 2001) . The TRIM5α isoform contains, in Virology 349 (2006) 300 -315 www.elsevier.com/locate/yviro addition to the RING, B-box 2 and coiled-coil domains, a carboxy-terminal B30.2(SPRY) domain. The B30.2(SPRY) domain is essential for the antiretroviral activity of TRIM5α . In some cases, the differences in the ability of TRIM5α proteins from various primate species to restrict particular retroviruses are determined by sequences in the B30.2(SPRY) domain Nakayama et al., 2005; Yap et al., 2005; Sawyer et al., 2005; Perez-Caballero et al., 2005) . Disruption of the B-box 2 domain of rhesus monkey TRIM5α (TRIM5α rh ) also eliminates the ability of the protein to restrict HIV-1 infection (Javanbakht et al., 2005; Perez-Caballero et al., 2005) . Deletion of the RING domain decreases, but does not eliminate, TRIM5α rh -mediated restriction of HIV-1 infection (Javanbakht et al., 2005; Perez-Caballero et al., 2005) . TRIM5, like other TRIM proteins, self-associates to form cytoplasmic bodies when overexpressed in cells (Reymond et al., 2001; Xu et al., 2003; Song et al., 2005b) . The nature and function of cytoplasmic bodies are unknown, but they are not required for the antiretroviral activity of rhesus monkey TRIM5α (Song et al., 2005b; Perez-Caballero et al., 2005) .
Here, we study the intracellular location, synthesis and turnover of wild-type TRIM5α rh and TRIMCyp and variants of these proteins with deletion or disruption of particular TRIM5 domains. We document several unusual features of TRIM5α and TRIMCyp, i.e., their rapid turnover, polyubiquitylation and association with pre-aggresomal structures in the cell. We show the importance of RING and B-box 2 domains to the polyubiquitylation and degradation of these proteins by the proteasome. Finally, we investigate the contribution of rapid turnover to the antiviral activity of TRIM5α.
Results
TRIM5α rh and TRIM5α hu are short-lived proteins
The rhesus monkey and human TRIM5 variants studied herein are depicted in Fig. 1A . In addition to TRIM5 mutants with domain deletions, the C15A/C18A and C97A/H100A mutants, in which the TRIM5α rh RING and B-box 2 domains, respectively, are disrupted Javanbakht et al., 2005) , were studied. These proteins were stably expressed in HeLa cells. The steady-state levels of these proteins were analyzed by Western blotting cell lysates with an antibody directed against the carboxy-terminal HA epitope tag ( Fig.  1B) . Compared with the expression of the wild-type TRIM5α rh protein, the levels of the Δ93, C15A, C15A/C18A and C97A/ H100A mutants were slightly higher. The Δ132 mutant was expressed at significantly higher levels than the wild-type TRIM5α rh protein. To investigate these differences, we determined the turnover rates of the TRIM5 variants by treating the HeLa cells with cycloheximide for a period of 12 h and assessing the level of TRIM5 protein expression at different time points after the initiation of cycloheximide treatment ( Fig. 2A) . Remarkably, after only 3 h of treatment with the drug, TRIM5α rh and TRIM5α hu levels were almost undetectable. Interestingly, TRIM5γ rh , a TRIM5 isoform that does not contain the B30.2(SPRY) domain ( Fig. 1A) , exhibited a similar rate of degradation ( Fig. 2A) . The approximate halflives of TRIM5α rh , TRIM5α hu and TRIM5γ rh were 52, 57 and 64 min, respectively. TRIM5α rh exhibited a similar rate of degradation in Cf2Th cells canine thymocytes (data not shown). We conclude that wild-type human and monkey TRIM5α proteins are turned over very rapidly in these transduced cells. The rapid degradation of the TRIM5γ rh protein further suggests that the B30.2(SPRY) domain is not needed for this fast turnover.
The TRIM5α rh RING and B-box 2 domains are important for rapid degradation
To address the possible role of the RING and B-box 2 domains in the rapid degradation of TRIM5α rh , we measured the half-lives of TRIM5α rh proteins containing deletions and single amino acid changes affecting the RING and B-box 2 domains ( Fig. 1A) . Interestingly, we observed two different rates of degradation for these mutants. Mutants containing single amino acid changes designed to disrupt zinc binding of the RING and B-box 2 domains (C15A/C18A and C97A/ H100, respectively) were degraded at a slower rate (half-lives of 124 and 148 min, respectively) than the wild-type protein ( Figs. 2A and B ). The TRIM5α rh Δ93 mutant, which lacks the RING domain, also exhibited a half-life of 124 min. A much slower rate of turnover (half-life of 764 min) was observed for the mutant (TRIM5α rh Δ132) with a deletion encompassing both the RING and B-box 2 domains ( Figs. 2A and B ). This half-life approached that seen for β-actin ( Figs. 2A and B) . These results suggest that the presence of an intact RING and B-box 2 domain contributes to the rapid degradation of TRIM5α rh .
TRIMCyp is a protein from owl monkeys that can restrict HIV-1 infection Sayah et al., 2004) . TRIMCyp consists of the RING, B-box 2 and coiled coil domains of TRIM5 fused with cyclophilin A. TRIMCyp exhibited a decay rate similar to that of TRIM5α rh (Fig. 2C ). TRIMCypΔ93, which lacks the RING domain, exhibited a steady-state level higher than that of TRIMCyp (Fig. 2C ). The turnover rate of the TRIMCypΔ93 protein was very slow, consistent with a role for the RING domain in the degradation of TRIMCyp. The decay rate of the TRIM-CypΔ130 protein, which lacks RING and B-box 2 domains, was only slightly slower than that of wild-type TRIMCyp (Fig. 2C ). Thus, deletion of the RING and B-box 2 domains results in different effects on the turnover of TRIM5α rh and TRIMCyp proteins.
Proteasomal inhibitors decrease the degradation of TRIM5α and TRIMCyp
To evaluate the role of the proteasome in the rapid turnover of TRIM5α rh and TRIM5α hu , TRIM5α levels were measured in the presence and absence of the proteasomal inhibitors, MG115 and lactacystin. The effects of proteasomal inhibitors were also examined in cycloheximide-treated cells. Compared with control cells treated with the DMSO solvent only, cells treated with the proteasomal inhibitors MG115 or lactacystin exhibited slight increases in TRIM5α levels over time (Figs. 3A and B and data not shown) . Compared with the initial levels of protein, this increase was 1.5-and 4-fold for TRIM5α rh and TRIM5α hu , respectively. We also measured the effect of MG115 on the rate of TRIM5α degradation in the presence of cycloheximide. MG115 decreased the turnover of TRIM5α rh and TRIM5α hu in this context as well ( Figs. 3A and B) . These results indicated that the proteasome contributes to the degradation of TRIM5α rh and TRIM5α hu . Similarly, treatment of cells synthesizing TRIMCyp with the proteasomal inhibitor MG115 resulted in an increase in the steady-state levels of TRIMCyp expression ( Fig. 3C ).
Most cytoplasmic proteins are degraded in the proteasome; another protein degradation pathway, most often used for transmembrane proteins, occurs in the lysosome (Cuervo and Dice, 1998) . To test if degradation of TRIM5α rh involves the lysosomal pathway, we measured the half-life of this protein in the presence of ammonium chloride (Fig. 3D ). This lysosomotropic agent did not change the half-life of TRIM5α rh , suggesting that the lysosome contributes minimally to the degradation of TRIM5α rh . Together, these results suggest that TRIM5α is mainly degraded in the proteasome.
TRIM5α rh is polyubiquitylated
As protein turnover by the proteasome is often associated with ubiquitylation (Hershko and Ciechanover, 1998), we tested if TRIM5α rh was mono-or polyubiquitylated. For this purpose, HeLa cells stably expressing TRIM5α rh tagged with a carboxy-terminal V5 epitope were transfected with a plasmid expressing an HA-epitope-tagged ubiquitin. Fortyeight hours later, cells were lysed and the lysates precipitated with an anti-V5 antibody. The precipitates were resolved on SDS-polyacrylamide gels and Western blotted using anti-V5 and anti-HA antibodies (Fig. 4A ).
Polyubiquitylated forms of TRIM5α rh were observed; furthermore, the steady-state level of TRIM5α rh and the detectable amount of polyubiquitylated TRIM5α rh increased after treatment with the proteasomal inhibitor MG115 (Fig. 4A ).
As RING domains are often associated with E3 ubiquitin ligase activity and the TRIM5δ hu RING domain has been implicated in self-ubiquitylation (Xu et al., 2003) , we , TRIM5γ rh , TRIM5α hu or the indicated TRIM5α rh mutants were treated with 100 μg/ml of cycloheximide (CHX) for a period of 12 h. At the indicated times after the beginning of the CHX treatment, cells were lysed. Cell lysates were Western blotted and probed with antibodies directed against either the HA epitope tag (top panels) or β-actin (bottom panels). These experiments were repeated three times for each individual construct, with similar results. (B) The density of each band in panel A was measured using an Eagle Eye densitometer (Stratagene). The logarithm of the percent initial amount of protein was plotted versus time (hours). The best curve was fit to the observed values. The half-life was determined by calculating the time required for a level of 50% of the initial amount of protein to be achieved. These experiments were performed at least 3 times, and typical results are shown. (C) HeLa cells expressing TRIMCyp, TRIMCypΔ93 or TRIMCypΔ130 tagged with a carboxy-terminal V5 epitope tag were treated with 100 μg/ml of cycloheximide (CHX) for a period of 6 h. At the indicated times after the beginning of the CHX treatment, cells were lysed. Cell lysates were Western blotted and probed with antibodies directed against either the V5 epitope tag (top panels) or β-actin (bottom panels). These experiments were performed three times for each individual construct, with similar results. examined the ubiquitylation of TRIM5α rh variants with deleted RING domains. Compared with wild-type TRIM5α rh , the TRIM5α rh Δ93 and TRIM5α rh Δ132 mutants exhibited more low-molecular-weight forms suggestive of mono-and di-ubiquitylation, and fewer high-molecular-weight, presumably polyubiquitylated, forms ( Fig. 4B) . Apparently, the RING domain contributes either directly or indirectly to polyubiquitylation of TRIM5α rh . Fig. 3 . Effect of proteasomal inhibitors on TRIM5α rh and TRIM5α hu turnover. (A) HeLa cells expressing TRIM5α rh and TRIM5α hu were treated with the DMSO solvent, 100 μg/ml cycloheximide (CHX) and/or 50 μM MG115 for a period of 6 h. Cells were harvested and lysed at the indicated times after the initiation of treatment. Cell lysates were Western blotted and probed with antibodies directed against either the HA epitope tag (top panels) or β-actin (bottom panels). (B) Curves describing TRIM5α levels as a function of time, based on the results in panel A, were generated as described in Fig. 2B legend. (C) HeLa cells expressing TRIM5Cyp were treated with 25 μM MG115 for a period of 6 h. Cells were harvested and lysed at the indicated time points after the initiation of treatment. Cell lysates were Western blotted and probed with antibodies directed against either the V5 epitope tag (top panel) or β-actin (bottom panel). (D) HeLa cells expressing TRIM5α rh and TRIM5α hu were treated with the DMSO solvent, 100 μg/ml cycloheximide (CHX) and/or 50 mM ammonium chloride for a period of 6 h. Cell lysates were processed as described in A and probed with antibodies directed against either the V5 epitope tag (top panels) or β-actin (bottom panels).
The ability of TRIM5α rh and TRIMCyp to restrict HIV-1 infection is not dependent upon the rapid degradation of these molecules Deletion of the RING domain reduces but does not eliminate the antiretroviral activity of TRIM5α rh (Javanbakht et al., 2005; Perez-Caballero et al., 2005) . Simultaneous deletion of the TRIM5α rh RING and B-box 2 domains results in a protein that does not restrict retroviruses. As shown above, the same deletions resulted in more stable TRIM5α proteins. Because the TRIM5α protein interacts with the viral capsid (Sebastian and Luban, 2005; in press), it is possible that the rapid turnover of TRIM5α affects the stability of the capsid and thus Fig. 4 . TRIM5α rh is polyubiquitylated. (A) HeLa cells transduced with the control pLenti vector or a vector stably expressing TRIM5α rh tagged with a carboxy-terminal V5 epitope were transiently transfected with a plasmid expressing HA-tagged ubiquitin. Forty-eight hours later, the cells were treated with MG115 or the DMSO solvent control for 6 h. Subsequently, cells were lysed, and proteins in the cell lysates were precipitated with an anti-V5 antibody. The immunoprecipitates were Western blotted and probed with an anti-V5 antibody for TRIM5α rh detection or an anti-HA antibody for ubiquitin detection. IP = immunoprecipitation; WB = Western blot. (B) 293T cells were transiently transfected with the empty vector plasmid (pcDNA6.2) or plasmids expressing TRIM5α rh -V5, TRIM5α rh Δ93-V5 or TRIM5α rh Δ132-V5 together with a plasmid expressing ubiquitin-HA. Forty-eight hours later, cells were lysed and proteins in the cell lysates were precipitated with an anti-V5 antibody. The precipitates were Western blotted and probed with an anti-V5 antibody for TRIM5α rh detection or an anti-HA antibody for ubiquitin detection. augments restricting ability. To test this hypothesis, we examined the relationship between TRIM5α turnover and viral restriction.
TRIM5α rh and TRIMCyp mutants lacking the RING domains are more stable than the corresponding wild-type proteins (see above). During the course of our studies, we found that a TRIM5α rh variant (TRIM5-21(RING)) bearing the RING domain of human TRIM21 exhibited a much slower rate of turnover than the wild-type TRIM5α rh protein (Fig. 5A) . Compared with half-lives of less than 60 min for the TRIM5α rh and TRIMCyp proteins, the half-lives of the TRIM5α rh Δ93, TRIMCypΔ93 and TRIM5-21(RING) proteins were 124, 900 and 210 min, respectively ( Fig. 5B ). To evaluate the contribution of rapid degradation to HIV-1 restriction, we challenged HeLa cells stably expressing the wild-type and mutant TRIM5α rh and TRIMCyp proteins with an HIV-1 vector encoding green fluorescent protein (HIV-1-GFP) (Fig. 5C ). The RING domain-deleted versions of TRIM5α rh and TRIMCyp retained substantial ability to inhibit HIV-1 infection, although the observed HIV-1-restricting activities were less than those of the respective wild-type proteins. The TRIM5-21(RING) protein restricted HIV-1 infection with a potency comparable to those of the wild-type TRIM5α rh and TRIMCyp proteins ( Fig. 5C ). Thus, rapid turnover is not an absolute requirement for the ability of TRIM5-related proteins to restrict HIV-1 infection.
TRIM5 colocalizes with polyubiquitylated proteins in aggresome precursors
For proteins that are misfolded or that are otherwise prone to self-associate, treatment of expressing cells with proteasomal inhibitors has been shown to decrease protein turnover and to cause accumulation of cytosolic aggregates (Johnston et al., 1998) . If the cytosolic unfolded protein response cannot refold or de-aggregate these proteins, the aggregates are transported in a microtubule-dependent manner to the microtubule-organizing center (MTOC) (Johnston et al., 2002; Riley et al., 2003) . This process clears the aggregates from the cytosol and concentrates them in a perinuclear structure called the aggresome. Aggresomes are often enveloped in vimentin cages and contain dynein, chaperones, ubiquitylation enzymes and proteasomal components (Garcia-Mata et al., 1999 Ito et al., 2002) . As TRIM5α rh appears to be rapidly cleared by the ubiquitin-proteasome pathway, we tested if polyubiquitylated proteins colocalize with TRIM5α rh . HeLa cells expressing TRIM5α rh with a carboxy-terminal HA epitope tag were stained with an FITCconjugated anti-HA antibody and with the FK2 antibody, which recognizes polyubiquitylated proteins (Fujimuro et al., 1994) . As has been previously observed (Javanbakht et al., 2005; Song et al., 2005b) , TRIM5α rh is present diffusely throughout the cytoplasm as well as in cytoplasmic bodies. The TRIM5α rh -containing cytoplasmic bodies are distinct from the cytoplasmic stress granules associated with the accumulation of untranslated mRNAs in cells subjected to environmental stress (Anderson and Kedersha, 2002 ) (data not shown). The TRIM5α rh protein in cytoplasmic bodies colocalized with polyubiquitylated proteins (Fig. 6A ). When the cells were treated with the MG115 proteasomal inhibitor, TRIM5α rh and polyubiquitylated proteins colocalized in a perinuclear structure resembling an aggresome. Similar results were obtained for TRIM5α hu (Fig. 8) .
Because aggresome formation is dependent on transport along microtubules (Johnston et al., 1998 (Johnston et al., , 2002 Riley et al., 2003) , we tested if nocodazole, a drug that prevents microtubule polymerization, would affect the formation of the perinuclear structures formed by TRIM5α rh in the presence of proteasomal inhibitors. Nocodazole treatment together with MG115 prevented the formation of a discrete perinuclear structure containing TRIM5α rh and polyubiquitylated proteins (Fig.  6A) . Instead, larger cytoplasmic bodies were observed in the Fig. 5 . Rapid TRIM5α rh degradation is not necessary for HIV-1 restriction. (A) HeLa cells were established that express TRIM5α rh bearing the RING domain of TRIM21 (TRIM5-21(RING)), with an HA epitope tag at the carboxylterminus. The cells were treated with 100 μg/ml of cycloheximide (CHX) for a period of 6 h. At the indicated times after the beginning of the CHX treatment, the cells were lysed. Cell lysates were Western blotted and probed with antibodies directed against either the HA epitope tag (top panels) or β-actin (bottom panels). These experiments were repeated three times with similar results. (B) The density of each band in panel A was measured using an Eagle Eye densitometer (Stratagene). The logarithm of the percent initial amount of protein was plotted versus time (hours). The best curve was fit to the observed values. The half-life was determined by calculating the time required for a level of 50% of the initial amount of protein to be achieved. These experiments were performed at least 3 times, and typical results are shown. TRIMCyp and TRIMCypΔ93 values were obtained from the experiment shown in Fig. 2C . TRIM5α rh , TRIM5α rh Δ93 and actin values were obtained from the experiment shown in Fig. 2B . (C) HeLa cells transduced with the empty LPCX vector or vectors expressing TRIM5α rh , TRIM5α rh Δ93, TRIMCyp, TRIMCypΔ93 or TRIM5-21(RING) were challenged with different amounts of HIV-1-GFP. Infected, GFP-positive cells were counted by FACS. Similar results were obtained in three independent experiments. nocodazole-and MG115-treated cells, compared with those seen in untreated cells. These larger bodies were distributed throughout the cytoplasm. Treatment of TRIM5α-expressing cells with nocodazole alone resulted in an increase in the number of cytoplasmic bodies, which coalesced and partially colocalized with cytoplasmic bodies containing polyubiquitylated proteins. The colocalization of TRIM5α rh and polyubiquitylated proteins in cytoplasmic bodies and the effects of proteasomal and microtubule inhibitors suggest that TRIM5α-associated cytoplasmic structures may be aggresome precursors.
To investigate further the possible link between TRIM5α cytoplasmic bodies and aggresomes, we tested whether TRIM5α rh colocalized with other proteins known to be associated with microtubules or aggresomes (Garcia-Mata et al., 1999) . TRIM5α rh colocalized with dynein ( Fig. 6B) , which is involved in a microtubule-directed transport of cytosolic protein aggregates to the MTOC Johnston et al., 1998 Johnston et al., , 2002 Rajan et al., 2001) . TRIM5α rh partially colocalized with the heat shock proteins, Hsp70 and Hsp90, which act as chaperones and are involved in the unfolded protein response (Fig. 6B) (Garcia-Mata et al., 1999; Wigley et al., 1999) . Moreover, γ-tubulin, an MTOC marker, was located in the vicinity of the perinuclear structures containing TRIM5α rh that formed in MG115-treated cells (Fig. 6C) . By contrast, the actin and microtubule cytoskeleton did not localize with the TRIM5α rh -associated structures formed after treatment with the proteasome inhibitor MG115 (Fig. 6C) . These results support an association between TRIM5α and components of the unfolded protein response.
The above results imply that TRIM5 levels in the cell are maintained by continuous synthesis and rapid degradation and that cytoplasmic bodies result when levels of synthesis overwhelm the cell's ability to fold or degrade the TRIM5 protein. This predicts that decreasing TRIM5 synthesis should result in a decrease in the number of cytoplasmic bodies in a cell. To test this prediction, HeLa cells stably expressing TRIM5α rh were treated with cycloheximide. At different times, cells were stained with an anti-HA antibody to determine TRIM5α rh -HA distribution in the cell. Fig. 7 shows that, by 2-4 h after cycloheximide treatment, the number of Fig. 6 . Proteasomal inhibitors cause relocation of TRIM5α to the aggresome. (A) HeLa cells expressing TRIM5α rh with an HA epitope tag were seeded on coverslips and treated for 6 h with DMSO, 25 μM MG115, 1 μg/ml nocodazole (NOC) or MG115 and nocodazole. Attached cells were first stained using a mouse antibody, FK2, directed against polyubiquitylated proteins and a secondary antibody against mouse IgG 1 labeled with Cy3 (red). Subsequently, TRIM5α rh was detected by using an anti-HA antibody conjugated to FITC (green). (B) HeLa cells expressing HA epitope-tagged TRIM5α rh were seeded on coverslips and stained with an anti-HA antibody conjugated to FITC. Cells were also stained with anti-dynein, anti-Hsp70 and anti-Hsp90 antibodies. These proteins were detected using anti-mouse IgG 1 conjugated to Alexa Fluor 568 (red) from Molecular Probes. Confocal images were taken using a 60× objective. (C) HeLa cells expressing TRIM5α rh with an HA epitope tag were seeded on coverslips and treated with DMSO or 25 μM MG115 for a period of 6 h. Cells were stained using an anti-α-tubulin antibody (Molecular Probes), phalloidin conjugated to Alexa Fluor 568 (red) to detect actin, or an anti-γ-tubulin antibody (Molecular Probes). To detect αand γ-tubulin, cells were stained with a secondary antibody against mouse IgG 1 labeled with Cy3 (red). TRIM5α rh was detected as previously described (green). cytoplasmic bodies in the cells decreased dramatically, as predicted.
Previous studies indicated that the integrity of the RING domain of TRIM5α rh could influence the subcellular localization of the protein (Javanbakht et al., 2005) . To examine the contribution of the RING, B-box 2 and B30.2 (SPRY) domains to association of TRIM5α with aggresomes, cells expressing TRIM5 variants were treated with DMSO or MG115 and stained with an antibody against the HA epitope at the carboxyl-terminus of the TRIM5 proteins. In the absence of the proteasomal inhibitor, TRIM5α hu , TRIM5α rh and TRIM5γ rh exhibited diffuse cytoplasmic staining as well as cytoplasmic body formation (Fig. 8 ). MG115 treatment resulted in the localization of all three proteins in perinuclear structures resembling aggresomes. Deletion of the TRIM5α rh RING domain resulted in relocalization of the TRIM5α rh Δ93 protein to nuclear bodies, with some faint and diffuse cytoplasmic staining. The staining pattern of the TRIM5α rh Δ93 proteins was not significantly affected by MG115 treatment (Fig. 8) . The TRIM5α rh C15A/C18A mutant, in which alteration of the RING domain cysteines involved in zinc binding is thought to disrupt the folding of the domain, was located in perinuclear bodies that became more intense upon treatment with MG115 (Fig. 8) . The TRIM5α rh C97A/H100A mutant with a disrupted B-box 2 domain was located in the cytosol in the absence of MG115 treatment (Fig. 8) . The TRIM5α rh Δ132 mutant lacking the RING and B-box 2 domains was located throughout the untreated cells, in both nuclear and cytoplasmic compartments (Fig. 8 ). Both TRIM5α rh C97A/H100A and Δ132 mutant proteins were found in aggresome-like structures after treatment of the cells with MG115. It appears that the RING, B-box 2 or B30.2(SPRY) domains are not absolutely required for TRIM5α rh association with the aggresome.
Autophagosome inhibition does not affect restriction activity of TRIM5α and TRIMCyp
Aggregate-prone proteins are, in some instances, dependent upon autophagy for clearance (Mizushima et al., 2002; Reggiori and Klionsky, 2005) . Autophagy involves sequestration of a portion of the cytosol within autophagosomes, which fuse with lyosomes to allow degradation of their contents. Cytoplasmic inclusion bodies associated with neurodegenerative protein aggregates have been shown to be susceptible to autophagic degradation (Ravikumar et al., 2002; Webb et al., 2003; Cuervo et al., 2004; Iwata et al., 2005) . To test whether autophagy is involved in TRIM5α clearance, we monitored the steady-state levels of TRIM5α rh in the presence of 3-methyladenine, an inhibitor of class III phosphatidylinositol 3-kinases that has been shown to block the formation of the autophagosome (Aki et al., 2003; Blommaart et al., 1997; Qin et al., 2003; Ravikumar et al., 2002) . The steady-state levels of soluble TRIM5α rh protein were not affected by 3-methyladenine treatment (Fig.  9A) . However, treatment with this drug did result in an increase in the size of the TRIM5α rh -associated cytoplasmic bodies (Fig.  9B) . The ability of TRIM5α rh and TRIMCyp to restrict HIV-1 infection was not affected by 3-methyladenine treatment (Fig.  9C ). Thus, autophagy may contribute to the processing of TRIM5α cytoplasmic bodies but is not necessary for the antiviral activity of TRIM5α rh or TRIMCyp.
Discussion
Like many cytoplasmic TRIM proteins (Reymond et al., 2001) , TRIM5α forms cytoplasmic bodies in addition to exhibiting a more diffuse cytosolic staining pattern. The nature, composition and function of these cytoplasmic bodies are unknown. Our results reveal several unusual features of TRIM5 (Fig. 10) . First, the TRIM5α hu , TRIM5α rh , TRIM5γ rh and TRIMCyp proteins undergo rapid turnover when expressed in HeLa and Cf2Th cells, with half-lives of approximately 1 h. In the vectors used to express these TRIM5 variants, the coding sequences from the TRIM5 cDNA are under the control of a strong constitutive promoter. The degradation rates of the TRIM5 proteins play an important role in determining the steady-state levels of the TRIM5 proteins in these transduced cells. In most natural cells, TRIM5 is expressed in a constitutive fashion (Reymond et al., 2001) . It will be of interest to investigate the mechanisms that regulate the synthesis and turnover of TRIM5 messages and proteins in more natural contexts. The availability of TRIM5 antibodies should assist these studies.
Additional factors may play roles in establishing TRIM5 steady-state protein levels. For example, we have noted that HeLa cells appear to tolerate slightly higher stable levels of Fig. 7 . TRIM5α cytoplasmic bodies are maintained by protein synthesis. HeLa cells expressing TRIM5α rh with a carboxy-terminal HA epitope tag were seeded on coverslips. Cells were treated with 100 μg/ml cycloheximide (CHX) for the indicated times (hours). Cells were stained with an FITC-conjugated anti-HA antibody. Confocal images were taken using a 60× objective. Cytoplasmic bodies were counted in 200 randomly chosen cells at each time point. The counts were performed in triplicate, and means and standard deviations are reported. expression of TRIM5α rh than TRIM5α hu . The basis for cellular limits on the amounts of TRIM5 protein that are stably tolerated is unknown. However, the RBCC domains of some TRIM proteins, e.g., TRIM27 (Ret finger protein) and HLS5, exert pro-apoptotic effects on cells (Dho and Kwon, 2003; Lalonde et al., 2004) . The expression of aggregation-prone proteins in cells has also been suggested to impair the general function of the ubiquitin-proteasome system (Bennett et al., 2005) , and, in light of the observed association between TRIM5 and the aggresome, such effects may contribute to cellular limits on levels of TRIM5 expression.
A second unusual feature of TRIM5, and TRIM proteins in general, is the tendency to self-associate into large collections of protein. Many TRIM proteins homo-oligomerize (Reymond et al., 2001) ; moreover, these homo-oligomers can associate to form higher-order structures that are detectable in cell lysates and probably manifest in intact cells as cytoplasmic bodies. Cytoplasmic bodies are sensitive to the amount of TRIM5α protein present in the cell; the size of TRIM5α-associated cytoplasmic bodies decreases when TRIM5α synthesis is decreased, as upon cycloheximide treatment. Conversely, the size and/or number of cytoplasmic bodies increase when pathways for TRIM5α degradation are suppressed, as when the proteasome or microtubule-dependent transport pathway is inhibited. Treatment of cells with proteasome inhibitors results in the coalescence of TRIM5α-containing cytoplasmic bodies into aggresomes. Most proteins do not move into aggresomes upon inhibition of the proteasome. Mutant proteins prone to unfolding have been shown to exhibit higher propensity to be incorporated into aggresomes upon proteasomal inhibition Ito et al., 2002; Johnston et al., 1998; Wigley et al., 1999) . Aggregate-prone proteins associate with chaperones, which break up the aggregates and refold aberrant proteins into native conformations Johnston et al., 1998; Wigley et al., 1999) . It is likely that such processes operate on TRIM5 and other polyubiquitylated proteins in the context of the cytoplasmic body. Indeed, inhibition of the chaperone Hsp90 by geldanamycin resulted in the reduction or disappearance of TRIM5α-associated cytoplasmic bodies (Song et al., 2005b) . Proteasomal inhibition in the cells overexpressing TRIM5 apparently overwhelms the cytosolic unfolded protein response, triggering the coalescence of the cytoplasmic bodies into aggresomes. Thus, cytoplasmic bodies probably represent aggresomal precursors, linked to the aggresome by microtubular transport.
Our results suggest that the TRIM5α rh RING and B-box 2 domains play roles in the polyubiquitylation and turnover of the Fig. 8 . The effect of proteasome inhibition on cellular location of TRIM5α variants. Control HeLa cells transduced with the LPCX vector or HeLa cells expressing TRIM5α rh , TRIM5γ rh , TRIM5α hu or the indicated TRIM5α rh mutants were seeded on coverslips. Attached cells were treated with the DMSO control or 25 μM MG115 for a period of 6 h. Cells were stained with an FITC-conjugated anti-HA antibody. Confocal images were taken using a 60× objective.
protein. Disruption or deletion of the RING and B-box 2 domains had additive effects on the turnover rate of TRIM5α rh . TRIM5α rh variants lacking the RING or RING/B-box 2 domains exhibited fewer polyubiquitylated forms than the wild-type protein, even though mono-and di-ubiquitylated forms were evident for these mutants. It is plausible that the phenotypes of these variants with respect to polyubiquitylation and turnover rate are related. Whether the TRIM5α RING and/ or B-box 2 domains contribute directly or indirectly to these phenotypes requires further investigation. RING domains often promote protein-protein interactions important for cellular functions (Borden, 2000; Saurin et al., 1996) . RING domains from diverse proteins, including AO7, Praja1, Kf-1, NFX-1 and TRC8, have been demonstrated to possess in vitro E3 ubiquitin ligase activity allowing selfpolyubiquitylation (Lorick et al., 1999) . TRIM5δ has been reported to be capable of self-ubiquitylation in vitro (Xu et al., 2003) . B-box domains have also been shown to contribute directly or indirectly to protein-protein interactions (Cao et al., 1997 (Cao et al., , 1998 Torok and Etkin, 2001) .
Although the RING and B-box 2 domains contribute to TRIM5α rh turnover and polyubiquitylation, they are not absolutely required for TRIM5 localization in pre-aggresomal structures, as the TRIM5α rh Δ132 proteins are found in aggresomes after MG115 treatment. One caveat in interpreting the contributions of particular domains to TRIM5 localization is that proteins missing domains may be more prone to aggregation due to lack of natural interdomain interactions. Thus, even though RING, B-box and coiled-coil domains are often treated as functionally independent entities, there is evidence to support the notion that RBCC domains work as an integral unit. Alterations in multiple RBCC regions of TRIM19 (PML) can result in disruption of nuclear bodies (Borden et al., 1995 . Substitution of the TRIM19 (PML) RING and Bbox domains with heterologous RING or B-box domains does not rescue TRIM19 (PML) function (Borden, 2000) . Thus, observed associations of TRIM5 variants with cytoplasmic bodies or aggresomes may result from disruption of the natural context of the RBCC domains rather than the discrete disruption of a single domain important per se for localization in the cell.
TRIM5α is thought to interact with the incoming capsid of the restricted virus (Sebastian and Luban, 2005; Stremlau et al., in press) . Hypothetically, the bound capsid could passively undergo rapid turnover as a result of the association with the unstable TRIM5α protein, contributing to the restriction of infection. However, polyubiquitylation and/or rapid turnover of TRIM5α appear not to be essential for retroviral restriction. Disruption of the RING domain of TRIM5α rh diminishes, but does not eliminate, the ability to restrict HIV-1 infection (Fig. 5C) (Javanbakht et al., 2005; Perez-Caballero et al., 2005) . Some of this diminution in antiviral activity is likely due to the mislocalization of the protein in the nucleus (in the case of the TRIM5α rh Δ93 mutant) or in perinuclear structures (in the case of the Fig. 9 . Inhibition of autophagosomes affects the size of cytoplasmic bodies but does not disrupt retroviral restriction. (A) Cf2Th cells expressing HA-tagged TRIM5α rh were treated with 10 mM 3-methyladenine (3-MA) (Sigma) for a period of 18 h. At the indicated times after the beginning of the 3-MA treatment, cells were lysed. Cell lysates were Western blotted and probed with antibodies directed against either the HA epitope tag (top panels) or β-actin (bottom panels). These experiments were repeated three times with similar results. (B) Cf2Th cells expressing HA-tagged TRIM5α rh were grown on 12 mm coverslips and treated with 10 mM 3-MA for a period of 3 and 12 h. Cells were fixed and stained using an FITC-conjugated anti-HA antibody, as described in Materials and methods. (C) Cf2Th cells transduced with the empty LPCX vector or vectors expressing TRIM5α rh and TRIMCyp were challenged with different amounts of HIV-1-GFP, in the presence or absence of 3-MA. These experiments were repeated three times with similar results. Fig. 10 . Synthesis and turnover of TRIM5α. The diagram depicts the high rates of synthesis and proteasomal degradation of TRIM5α. Excess free TRIM5α may aggregate and become incorporated into cytoplasmic bodies. The cytoplasmic bodies apparently migrate along microtubules to the perinuclear region, where they coalesce into the aggresome at the microtubule-organizing center. The sites of action of some of the drugs used herein and in another study (Song et al., 2005b) to alter TRIM5α synthesis, turnover or intracellular fate are depicted.
TRIM5α rh C15A/C18A mutant). TRIMCyp lacking its RING domain is a very stable protein but still exhibits good anti-HIV-1 activity. Likewise, a TRIM5α rh variant containing the RING domain of TRIM21 exhibited a slower turnover compared to wild-type TRIM5α rh . However, this chimera restricted HIV-1 infection as potently as wild-type TRIM5α rh . Finally, inhibition of the proteasome by clasto-lactacystin βlactone did not diminish the HIV-1-restricting activity of TRIM5α rh (Stremlau et al., in press) . These experiments suggest that polyubiquitylation and/or rapid turnover is not required for TRIM5α rh antiretroviral activity. Nonetheless, the high rates of TRIM5α and TRIMCyp turnover create opportunities for the rapid regulation of the levels of these proteins in response to viral infection or other stimuli. Further studies should shed light on these possibilities.
Materials and methods

Plasmid construction
The plasmids expressing wild-type and mutant TRIM5α rh were constructed by polymerase chain reaction (PCR) amplification of TRIM5α rh cDNA, as previously described . The amplified fragments were cloned into the EcoRI and ClaI sites of pLPCX (Stratagene). The plasmids expressing TRIM5α rh -V5 and TRIMCyp were constructed by inserting PCR-amplified TRIM5α rh or TRIMCyp cDNA into the Viral Power plasmid using directional TOPO® cloning (Invitrogen). Plasmids expressing TRIM5α rh with single amino-acid changes were created by QuikChange mutagenesis (Stratagene). The nomenclature for these mutants is TRIM5α rh followed by the wild-type amino acid residue in single-letter code, amino acid position and the amino acid residue to which the change was made.
Creation of cells stably expressing TRIM5α and TRIMCyp variants
Retroviral vectors encoding wild-type or mutant TRIM5α rh proteins were created using the pLPCX vector plasmid . The pLPCX vectors contain only the amino acid coding sequence of the TRIM5α cDNA. The TRIM5α rh proteins encoded by the pLPCX vectors possess Cterminal epitope tags derived from influenza hemagglutinin (HA). Recombinant viruses were produced in 293T cells by cotransfecting the pLPCX plasmids with the pVPack-GP and pVPack-VSV-G packaging plasmids (Stratagene). The pVPack-VSV-G plasmid encodes the vesicular stomatitis virus (VSV) G envelope glycoprotein, which allows efficient entry into a wide range of vertebrate cells.
TRIM5α rh -V5 and TRIMCyp-V5 proteins were expressed using the Viral Power system (Invitrogen). The TRIM5α rh -V5 and TRIMCyp-V5 proteins possess a V5 C-terminal epitope tag. Recombinant lentiviruses were produced according to the manufacturer's protocol (Invitrogen). The resulting virus particles were used to transduce approximately 1 × 10 6 HeLa cells in the presence of 5 μg/ml polybrene. Cells were selected in either 1 μg/ml puromycin (Sigma) or 2 μg/ml blasticidin (Invitrogen).
Determination of TRIM5 and TRIMCyp half-life
HeLa cells expressing the different TRIM5 variants were seeded in 6-well plates at 40% confluency 1 day prior to the experiment. Cells were treated with 100 μg/ml of cycloheximide (Sigma) to block protein synthesis and harvested at different time points. Cell lysates were prepared and Western blotted using the anti-HA antibody 3F10 (Roche). Protein band densities were determined using Eagle Eye II (Stratagene). The half-life of the protein was calculated by plotting the log (percent initial amount of protein) versus time in hours. Proteasomal inhibitors MG115 and clasto-lactacystin β-lactone (Calbiochem) were used at 25-50 μM and 10 μM, respectively. Ammonium chloride (Sigma) was used at 50 mM final concentration.
Protein analysis
Cellular proteins were extracted with radioimmunoprecipitation assay (RIPA) buffer (10 mM Tris, pH 7.4; 100 mM NaCl; 1% sodium deoxycholate; 0.1% sodium dodecyl sulfate [SDS]; 1% NP-40; 2 mg of aprotinin/ml; 2 mg of leupeptin/ ml; 1 mg of pepstatin A/ml; 100 mg of phenylmethylsulfonyl fluoride/ml). The cell lysates were analyzed by SDS-PAGE (10% acrylamide) followed by blotting onto nitrocellulose membranes (Amersham Pharmacia Biotech). Detection of protein by Western blotting utilized monoclonal antibodies that are specifically reactive with the HA (Roche) or V5 (Invitrogen) epitope tags and monoclonal antibody against βactin (Sigma). Detection of proteins was performed by enhanced chemiluminescence (NEN Life Sciences Products), using the following secondary antibodies obtained from Amersham Pharmacia Biotech: anti-mouse (for V5 and βactin) and anti-rat (for HA).
Ubiquitylation of TRIM5α
To study TRIM5α ubiquitylation, 293T cells were transfected with plasmids encoding wild-type or mutant TRIM5α rh together with a plasmid expressing HA-tagged ubiquitin (kindly provided by Dr. Bettina Strack) using Lipofectamine 2000 (Invitrogen). Forty-eight hours later, cells were harvested and lysed in RIPA buffer. Extracts were precipitated using a mouse anti-V5 antibody. Immunoprecipitated proteins were Western blotted and separately probed with a horseradish-peroxidase (HRP)-conjugated anti-V5 antibody (Invitrogen) or an HRP-conjugated anti-HA antibody (Roche).
Infection with viruses expressing green fluorescent protein (GFP)
Recombinant HIV-1 expressing GFP were prepared as described . HIV-1 viral stocks were quantified by measuring reverse transcriptase (RT) activity. For infections, 3 × 10 4 HeLa cells seeded in 24-well plates were incubated in the presence of virus for 24 h. Cells were washed and returned to culture for 48 h and then subjected to FACS analysis with a FACScan (Becton Dickinson).
Intracellular location of TRIM5 variants
Localization of TRIM5 was studied as previously described (Diaz-Griffero et al., 2002) . Briefly, cells were grown overnight on 12-mm-diameter coverslips and fixed in 3.9% paraformaldehyde (Sigma) in phosphate-buffered saline (PBS; Cellgro) for 30 min. Cells were washed in PBS, incubated in 0.1 M glycine (Sigma) for 10 min, washed in PBS and permeabilized with 0.05% saponin (Sigma) for 30 min. Samples were blocked with 10% donkey serum (Dako, Carpinteria, CA) for 30 min and incubated for 1 h with antibodies. HA-tagged proteins were stained using an anti-HA FITC-conjugated antibody, clone 3F10 (Roche). Polyubiquitylated proteins were stained using a mouse monoclonal antibody, FK2 (Affinity Research Products). Mouse monoclonal antibodies AC88 and C92F3A-5 against Hsp90 and Hsp70, respectively, were obtained from Stressgen. The mouse monoclonal antibody clone 74.1 against dynein was obtained from Chemicon International. Monoclonal antibodies against αand γ-tubulin were purchased from Molecular Probes. Actin filaments were stained using phalloidin conjugated to Alexa 568 (Molecular Probes). Subsequently, samples were mounted for fluorescence microscopy by using the ProLong Antifade Kit (Molecular Probes, Eugene, OR). Images were obtained with a BioRad Radiance 2000 laser scanning confocal microscope with Nikon 60× N.A.1.4 optics.
